Clinical Trial

Cardiovascular Disease Prevention Strategies for High-risk Urban Sedentary Employees in Karachi, Pakistan

Study acronym: m-LIfE
Recruiting
View on ClinicalTrials.gov →
Summary
Heart diseases and other non-communicable diseases are serious health issues in countries like Pakistan. Many people who work in offices, like bank employees, sit for more than 8 hours a day. This is called a sedentary lifestyle, and it increases the risk of heart diseases. This research project aims to find out if a newly developed context specific mobile phone application can help these sedentary employees to improve their lifestyle. The app, called m-LIfE (mHealth-based Lifestyle Intervention for Employees), will be designed to help employees to move more during the day and eat healthier food like fruits and vegetables. The study will involve bank employees in urban Karachi, Pakistan. They will be divided into two arms: Intervention arm: Participants in this arm will use the m-LIfE app for 12 weeks. They will get reminders and tips to take breaks, exercise, and eat healthy. Routine care arm: Participants in this arm will receive printed basic educational material about prevention of risk factors of heart diseases and improving lifestyle. After the 12 weeks of intervention, there will be a follow-up period at 4th week to check if participants are maintaining healthy habits. This study could help find simple and affordable ways to improve the health of office workers and reduce pressure on the healthcare system.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-13
notable Primary completion pushed: 2026-06 -> 2026-10 2026-08-13
minor Completion pushed: 2026-08 -> 2026-11 2026-08-13
Trial Details
NCT Number NCT06981247
Lead Sponsor Aga Khan University
Collaborators: Fogarty International Center of the National Institute of Health
Conditions Physical Activity, Life Style, Dietary Habits, Cardiovascular Diseases
Enrollment 84 participants
Start Date 2026-06-22
Primary Completion 2026-10 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-12